Gilead Sciences
Latest statistics and disclosures from Gilead Sciences's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RCUS, Galapagos Nv-, ASMB, KYTX, Xilio Therapeutics, and represent 100.00% of Gilead Sciences's stock portfolio.
- Added to shares of these 1 stock: ASMB (+$13M).
- Reduced shares in these 1 stock: ACLX (-$772M).
- Sold out of its position in ACLX.
- Gilead Sciences was a net seller of stock by $-759M.
- Gilead Sciences has $1.6B in assets under management (AUM), dropping by -22.15%.
- Central Index Key (CIK): 0000882095
Tip: Access up to 7 years of quarterly data
Positions held by Gilead Sciences consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Gilead Sciences
Gilead Sciences holds 5 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Arcus Biosciences Incorporated (RCUS) | 58.8 | $969M | 31M | 30.83 |
|
|
| Lakefront Biotherapeutics Spon Adr | 30.3 | $500M | 17M | 29.94 |
|
|
| Assembly Biosciences Com New (ASMB) | 8.3 | $137M | +10% | 5.0M | 27.48 |
|
| Kyverna Therapeutics (KYTX) | 2.2 | $37M | 4.1M | 8.91 |
|
|
| Xilio Therapeutics | 0.4 | $6.2M | 650k | 9.58 |
|
Past Filings by Gilead Sciences
SEC 13F filings are viewable for Gilead Sciences going back to 2024
- Gilead Sciences 2026 Q2 filed Aug. 3, 2026
- Gilead Sciences 2026 Q1 filed May 8, 2026
- Gilead Sciences 2025 Q4 filed Feb. 12, 2026
- Gilead Sciences 2025 Q3 filed Nov. 13, 2025
- Gilead Sciences 2025 Q2 filed Aug. 14, 2025
- Gilead Sciences 2025 Q1 filed May 13, 2025
- Gilead Sciences 2024 Q4 filed Feb. 13, 2025